Certara (NASDAQ:CERT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Key Points

• Certara reported quarterly EPS of $0.09, missing analyst expectations by $0.02 and down from $0.14 a year ago. Revenue rose only 0.8% year over year.
• The company updated its FY 2026 guidance to an EPS range of $0.35 to $0.41. Despite the earnings miss, Certara maintained a positive return on equity of 4.20%.
• Analyst sentiment is mixed, with recent target cuts and one downgrade, but the stock still carries a Moderate Buy consensus and an average price target of $10.44.

Certara (NASDAQ:CERT - Get Free Report) released its quarterly earnings results on Monday. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by ($0.02), Briefing.com reports. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.During the same period last year, the company posted $0.14 EPS. The business's quarterly revenue was up .8% compared to the same quarter last year. Certara updated its FY 2026 guidance to 0.350-0.410 EPS.

Certara Price Performance

Certara stock opened at $6.31 on Monday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. The company's 50-day moving average is $6.25 and its 200-day moving average is $8.11. The firm has a market capitalization of $967.45 million, a PE ratio of -631.00 and a beta of 1.53. Certara has a fifty-two week low of $5.19 and a fifty-two week high of $13.88.

Analyst Ratings Changes

A number of research analysts recently weighed in on CERT shares. Wall Street Zen downgraded shares of Certara from a "buy" rating to a "hold" rating in a research report on Sunday, February 15th. Barclays restated an "equal weight" rating and set a $8.00 price objective on shares of Certara in a research note on Friday, March 6th. TD Cowen restated a "buy" rating on shares of Certara in a report on Thursday, February 26th. Leerink Partners reiterated an "outperform" rating and set a $10.00 target price on shares of Certara in a report on Thursday, February 26th. Finally, KeyCorp reduced their price target on Certara from $10.00 to $8.00 and set an "overweight" rating for the company in a research report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $10.44.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently bought and sold shares of CERT. Wasatch Advisors LP lifted its position in shares of Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company's stock valued at $158,335,000 after buying an additional 4,244,230 shares during the last quarter. Deerfield Management Company L.P. raised its stake in Certara by 71.7% in the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company's stock valued at $82,357,000 after acquiring an additional 2,813,438 shares during the period. Ameriprise Financial Inc. raised its stake in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company's stock valued at $63,889,000 after acquiring an additional 1,165,064 shares during the period. UBS Group AG increased its holdings in shares of Certara by 106.3% in the third quarter. UBS Group AG now owns 1,651,955 shares of the company's stock valued at $20,187,000 after purchasing an additional 851,249 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of Certara by 580,097.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company's stock worth $7,310,000 after buying an additional 829,540 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company's offerings are divided into software tools and consulting services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.